Investor Presentaiton

2023 Key News Flow Asset Timing Opdivo EU approval in Neo-Adj. Lung EFS EU Approval June 2023 (CM-816) Opdivo Study Discontinued¹ 1L mCRPC Ph3 (CM -7DX) Opdualag Stage IV 1L NSCLC Ph2 (CA227-104) repotrectinib ROS1+ NSCLC (TRIDENT-1) filing | Abecma 3-5L MM (KarMMa-3) filing Breyanzi EU approval in 2L LBCL (Transplant Eligible) Breyanzi 3L+ CLL Ph1/2 (TRANSCEND-CLL) Breyanzi 2L & 3L+FL Ph2 (TRANSCEND-FL) ll Bristol Myers Squibb Q3 2023 Results 1H 2024 Priority Review: U.S. PDUFA November 27, 2023 U.S. PDUFA December 16, 2023; filed in EU & Japan EU approval May 2023 Met primary endpoint in January 2023 Presented at ASCO 2023 Positive topline results in April 2023 Presented at ICML 2023 ¹Did not meet primary endpoints of rPFS at FA nor OS at IA Reblozyl Asset EU approval in NTD Beta-Thalassemia Associated Anemia Reblozyl 1L TD MDS Associated Anemia (COMMANDS) filing Sotyktu EU approval in mod-to-severe PsO POETYK PSO-1 & PSO-2 Sotyktu Crohn's Disease Ph2 (LATTICE-CD) Sotyktu Ulcerative Colitis (higher dose) Ph2 (IMO11-127) LPA₁ Antagonist Progressive Pulmonary Fibrosis (PPF) Ph2 (IM027-040) Camzyos EU approval in symptomatic obstructive HCM (EXPLORER-HCM) Camzyos U.S. & EU approval in obstructive HCM SRT eligible (VALOR) Milestones represent data readouts or approvals unless otherwise specified; subject to positive registrational trials and health authority approval Timing EU Approval March 2023 Presented at ASCO & EHA 2023 U.S. approval August 2023 & filed in EU & Japan EU Approval March 2023 PoC not achieved PoC not achieved Achieved PoC EU Approval June 2023 U.S. & EU approval June 2023 Not for Product Promotional Use 25

View entire presentation